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36 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3and -49(G > T) from the transcription start site. We could demon-
strate that the variants -186(GGGC)5 (p < 0.05), and -49T (p = 0.05)
were significantly or strongly associated with colorectal cancer
as compared to the healthy controls. We found the highest pro-
moter activity to be associated with -186(GGGC)3 and -49T.
Conclusion: These results suggest that the two pKi-67 promoter
polymorphisms 186(GGGC)3 > (GGGC)5 and -49G > T located in the
basic promoter may play a crucial rule in the development of
colorectal cancer.
doi:10.1016/j.ejcsup.2006.04.084
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Introduction: Ample evidence indicates that MMPs contribute in
multiple ways to all stages of malignant progression, including
tumor invasion, blood vessel penetration, metastases and tumor
angiogenesis. MMP-9 has been found to be specifically associated
with prostate cancer metastasis. A number of DNA polymor-
phisms in the MMP genes are associated with differences in
MMP activity. However, the relationship between the polymor-
phism and susceptibility of cancer remains ambiguous. A cyto-
sine (C) – thymidine (T) single nucleotide polymorphism (SNP)
at position -1562 in the MMP-9 promoter is reported to affect
expression of this gene.
Aim: To determine the prevalence of a single nucleotide poly-
morphism (-1562 C/T) in the MMP-9 gene promoter in cancer
patients and evaluate it’s correlation with tumor type and stage.
Methods and Materials: DNA from the cancer patients’ blood
was extracted and amplified with PCR. PCR-RFLP method was
used to determine MMP-9 polymorphism in 18 prostate cancer
cases, 4 benign prostate hyperplasia cases, 14 invasive bladder
cancer cases, 5 non-invasive bladder cancer cases, 4 renal cancer
cases and 1 adrenal gland cancer case.
Results: Prevalence of C/C, C/T, T/T genotypes was similar
among bladder and renal cancer patients. In prostate cancer
patients a significant association (P = 0.0052) between clinical
stage and MMP-9 polymorphism was found.
Conclusion: Our data demonstrate that MMP-9 (-1562 C/T) poly-
morphism may modify susceptibility to prostate cancer. We
hypothesized that this polymorphism might act as a genetic
modifier in the development and progression of prostate cancer.
Additional studies with larger population are warranted.
doi:10.1016/j.ejcsup.2006.04.085
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Background: Despite compelling data demonstrating a direct
link between altered expression of S100 proteins located on
human chromosome 1q21 and epithelial malignancies, the
knowledge of their function and mode of action in epithelial cells
and in tumor promotion or progression is largely unknown.
Methods: Gene expression profiling of the in vivo model of
chemically induced skin carcinogenesis revealed differential reg-
ulation of genes coding for S100 proteins. Subsequent studies
using in vitro models and tissue microarrays are currently
extended by to suitable in vivo models.
Results: Here, we have identified a novel signaling pathway in
epithelial cells initiated by extracellular S100A8/A9 resulting in
the activation of AP-1-dependent gene expression. Importantly,
co-expression of S100A3 inhibits S100A8/A9 mediated AP-1 acti-
vation, which is in line with repression of this gene during skin
carcinogenesis suggesting a negative role for S100A3 in epithelial
malignancy. We found elevated levels of MMP2 and MMP9, two
well-known AP-1 regulated genes, and identified S100A6 as an
additional target gene of S100A8/A9 signaling. Moreover, signifi-
cant co-expression of S100A8 and S100A9 together with phos-
phorylation of c-Jun and elevated S100A6 protein levels were
evident in eSCC. The in vivo relevance of S100A8/A9 interaction
with RAGE is discussed.
Conclusion: Our data suggest that targeting the net activity of
S100 induced signaling represents an auspicious strategy for can-
cer prevention and/or therapy.
doi:10.1016/j.ejcsup.2006.04.086
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Background: One of the most common properties of cancer is
genomic instability, a leading cause of which are defects of the
DNA damage response (DDR). DDR defects in tumors and germ-
line have been linked to clinical outcome and cancer susceptibil-
ity, respectively. Among DDR regulators, the nuclear checkpoint
kinase Chk1 is an established transducer of ATR- and ATM-
dependent signalling in response to DNA damage. Additional
functions of Chk1 include regulation of unperturbed cell cycle
progression. Recently, we have shown that Chk1 localizes to inter-
